Floatz logo

flt3 ligand

Indolent B-cell Lymphomas

Celldex TherapeuticsPhase 1/2Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Indolent B-cell Lymphomas cohort.

Asset / SponsorPhaseRating
Ibrutinib
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Phase 3BB
CDX 1140
Celldex Therapeutics
Phase 1CC

Same molecule, other indications

flt3 ligand is also rated in:

Recurrent Renal Cell CancerDormant
B
Indicative ·
57 / 100
View asset →
Chronic Lymphocytic Leukemia (CLL)Dormant
CCC
Indicative ·
55 / 100
View asset →
Metastatic MelanomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →